BioRestorative Therapies (BRTX) Non Operating Interest Expenses (2010 - 2022)
BioRestorative Therapies' (BRTX) quarterly Non Operating Interest Expenses came in at $28841.0 in Q3 2022, down 94.18% on a YoY basis from $495545.0 in Q3 2021, and down 94.18% quarter-over-quarter from $495545.0 in Q3 2021.
Powered by 
Analysis
BioRestorative Therapies (BRTX) Non Operating Interest Expenses (2010 - 2022) Analysis & Trends
BioRestorative Therapies (BRTX) has reported Non Operating Interest Expenses for 11 consecutive years, with $28841.0 the latest figure, recorded in Q3 2022.
- For the quarter ending Q3 2022, Non Operating Interest Expenses fell 94.18% year-over-year to $28841.0; the trailing twelve-month figure through Sep 2022 stood at $543466.0 (up 1.18% YoY), and the FY2018 full-year result was $288986.0, up 976.7% from the prior year.
- Non Operating Interest Expenses eased to $28841.0 in Q3 2022 per BRTX's latest filing, from $495545.0 in the prior quarter.
- Across five years, Non Operating Interest Expenses topped out at $495545.0 in Q3 2021 and bottomed at $6769.0 in Q2 2020.
- Historically, Non Operating Interest Expenses has averaged $135866.5 across 3 years, with a median of $20576.0 in 2020.
- The sharpest annual moves came in 2021 and 2022: Non Operating Interest Expenses surged 3925.22% in 2021, then plunged 94.18% in 2022.
- Over 3 years, Non Operating Interest Expenses stood at $12311.0 in 2020, then soared by 3925.22% to $495545.0 in 2021, then slumped by 94.18% to $28841.0 in 2022.
- According to Business Quant data, Non Operating Interest Expenses over the past three periods registered $28841.0, $495545.0, and $12311.0 for Q3 2022, Q3 2021, and Q3 2020 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.60 Bn | 9.76 Bn | 112.79 Mn | - |
| 2 | CRISPR Therapeutics AG | 5.39 Bn | 5.39 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.98 Bn | 3.68 Bn | 55.72 Mn | 4.00 Bn |
| 4 | Legend Biotech | 3.97 Bn | 3.00 Bn | 251.50 Mn | -5.80 Mn |
| 5 | uniQure | 3.09 Bn | 3.09 Bn | 5.49 Mn | 14.37 Mn |
| 6 | Beam Therapeutics | 3.06 Bn | 3.06 Bn | - | - |
| 7 | Precigen | 2.54 Bn | 2.54 Bn | 52.17 Mn | 2.95 Mn |
| 8 | Sarepta Therapeutics | 2.38 Bn | 1.58 Bn | 251.87 Mn | - |
| 9 | Vericel | 2.06 Bn | 1.89 Bn | 56.40 Mn | 160,000.00 |
| 10 | BioRestorative Therapies | 62,133.68 | -2.89 Mn | 17,964.00 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2022 | 28,841.00 |
| Sep 30, 2021 | 495,545.00 |
| Sep 30, 2020 | 12,311.00 |
| Jun 30, 2020 | 6,769.00 |
| Dec 31, 2017 | 22,491.00 |
| Jun 30, 2016 | -27,886.00 |
| Mar 31, 2016 | 42,840.00 |
| Dec 31, 2015 | -181,916.00 |
| Sep 30, 2015 | 80,647.00 |
| Jun 30, 2015 | 60,096.00 |
| Mar 31, 2015 | 64,640.00 |
| Dec 31, 2014 | 64,974.00 |
| Sep 30, 2014 | 74,780.00 |
| Jun 30, 2014 | 72,390.00 |
| Mar 31, 2014 | 73,131.00 |
| Dec 31, 2013 | 85,342.00 |
| Sep 30, 2013 | 56,036.00 |
| Jun 30, 2013 | 32,035.00 |
| Mar 31, 2013 | 197,868.00 |
| Dec 31, 2012 | 128,244.00 |